Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2003

View Archived Issues

CT-3 effective in chronic neuropathic pain

Bax channel modulators as novel antiapoptotic compounds

Omega-3 fatty acids and antioxidants improve schizophrenia

New polyamine is effective and well tolerated in human prostate xenograft models

Novel VEGFR2 modulators prepared and tested at Pfizer

Merck KGaA team discovers new integrin inhibitors for thrombosis, cardiovascular disorders, etc.

New DPP-IV inhibitors covered by Sanofi-Synthelabo patent

Novel imaging agents with potential in the diagnosis and monitoring of AD patients

Yeda researchers claim new neurotrophic agents for schizophrenia and cognition deficits

New topical antiinflammatory agents and their use described by Japan Energy

Selective MMP-13 inhibitors synthesized by Aventis researchers

Topical bimosiamose studied in psoriasis and atopic dermatitis

Genentech product development events

FDA accepts Erbitux BLA for filing

Marketing approval sought for rasagiline in Europe

Nabi accelerates E.U. timeline for StaphVAX

Estrasorb approved for reduction of vasomotor symptoms in menopausal women

Approval for prefilled syringe presentation of Ovidrel

Xoma discontinues development of MLN-2201

AWD-12-353 exerts strong and long-lasting antiinflammatory effects in asthma and COPD

Unique class of dopamine D4-selective compounds under study at Schering-Plough and Neurogen

Posaconazole clinically effective in coccidioidomycosis

Anidulafungin as safe as fluconazole in esophageal candidiasis

Characterization of SU-10944, an orally active small-molecule inhibitor of VEGFR-2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...